secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-09-14T20:30:17+00:00
Accession:  0001193125-26-390652
Event type: m_and_a
Sentiment:  negative
Materiality: 0.80
Item codes: 2.01, 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics sells A-T assets to Ayma for $450K; President Ryan departs
------------------------------------------------------------------------------

- Completed sale of Quince SpA, AIDE IP, and eDSP machines to Ayma Therapeutics for $450,000 cash on Sept 8, 2026.
- Sale includes ~55 AIDE/eDSP machines: ~20 at Italian facilities, ~35 at clinical trial sites.
- President Charles Ryan separated Sept 8, 2026; severance of $1,014,489.04 under Separation Agreement.
- Pro forma financials assume sale effective Jan 1, 2025 for operations; balance sheet as of June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526390652/0001193125-26-390652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526390652/qncx-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-390652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer